The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Cancer with heavily economic and social burden is the hot point in the field of medical research. Some remarkable achievements have been made; however, the exact mechanisms of tumor initiation and development remain unclear. Cancer is a complex, whole-body disease that involves multiple abnormalities in the levels of DNA, RNA, protein, metabolite and medical imaging. Biological omics including genomics, transcriptomics, proteomics, metabolomics and radiomics aims to systematically understand carcinogenesis in different biological levels, which is driving the shift of cancer research paradigm from single parameter model to multi-parameter systematical model. The rapid development of various omics technologies is driving one to conveniently get multi-omics data, which accelerates predictive, preventive and personalized medicine (PPPM) practice allowing prediction of response with substantially increased accuracy, stratification of particular patients and eventual personalization of medicine. This review article describes the methodology, advances, and clinically relevant outcomes of different "omics" technologies in cancer research, and especially emphasizes the importance and scientific merit of integrating multi-omics in cancer research and clinically relevant outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174 · cited 2×
“The key aims of transcriptomics are to catalogue all species of transcripts, denote the transcriptional structure of gene, and quantify the expression level of each transcript during development and under different conditions [75].”
BackgroundMethodEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 7×
“For example, a study of 10 glioblastoma MRI features discovered that the ratio of enhancing to nonenhancing volume was correlated with EGFR overexpression.”
BackgroundInfluentialComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · cited 1×
“TCGA research network has showed the comprehensive genomic characterization of squamous cell lung cancers [44], gastric adenocarcinoma [45], human colon and rectal cancer [46], human glioblastoma [47], and ovarian carcinoma [48].”
BackgroundSequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066 · cited 17×
“In the aspect of raw accuracy, the NGS platforms are at least tenfold less accurate than Sanger sequencing [38].”
BackgroundMethodInfluentialMass spectrometry-based proteomics
Aebersold, R., & Mann, M. (2003) · Nature · doi:10.1038/nature01511 · Cited by 6,955
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · cited 1×
“TCGA research network has showed the comprehensive genomic characterization of squamous cell lung cancers [44], gastric adenocarcinoma [45], human colon and rectal cancer [46], human glioblastoma [47], and ovarian carcinoma [48].”
BackgroundThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Radiomics: extracting more information from medical images using advanced feature analysis
Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R. G. P. M., Granton, P., Zegers, C. M. L., Gillies, R., Boellard, R., Dekker, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.036 · Cited by 6,084
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Long non-coding RNAs: insights into functions
Mercer, T. R., Dinger, M. E., & Mattick, J. S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2521 · Cited by 5,654
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132 · cited 1×
“Analysis of radiomics-based features, comprehensive quantification information relating to the tumor phenotypes could be obtained [262, 263].”
BackgroundEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Long non-coding RNAs: new players in cell differentiation and development
Fatica, A., & Bozzoni, I. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3606 · Cited by 2,980
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“The accumulation of 2-HG inhibits 2-oxoglutarate-dependent oxygenases [240], impairs histone demethylation [241], blocks cell differentiation [242], and promotes tumorigenesis [243].”
BackgroundA rapid method for determining sequences in DNA by primed synthesis with DNA polymerase
Sanger, F., & Coulson, A. R. (1975) · Journal of Molecular Biology · doi:10.1016/0022-2836(75)90213-2 · Cited by 2,709 · cited 1×
“First, Sanger invented Bthe dideoxy method^ in 1977 [34], which improved the method of the previous Bplus and minus^ [35, 36] for DNA sequencing.”
MethodTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Radiomics: the process and the challenges
Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., Forster, K., Aerts, H. J. W. L., Dekker, A., Fenstermacher, D., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.010 · Cited by 2,258 · cited 1×
“This type of information is crucial for the diagnosis of tumors, but it does not accurately reflect the morphological and behavioral complexities of a tumor, with limited benefits in the judgment of treatment sensitivity and prognosis [255].”
BackgroundRNA sequencing: advances, challenges and opportunities
Ozsolak, F., & Milos, P. M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2934 · Cited by 2,135 · cited 1×
“gene structural feature to its functions and easier discover the causal of physiological or pathological conditions [87, 88].”
BackgroundWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
MicroRNA profiling: approaches and considerations
Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3198 · Cited by 1,765
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635 · cited 1×
“A series of oncometabolites have been identified, including 2hydroxyglutarate and glucose in gliomas and acute myeloid leukemia [226–228], fumarate in papillary kidney cancer [229], succinate in pheochromocytoma [230], sarcosine and choline in Pca [231, 232], glutamine in pancreatic [233, 234], asparagine in ovarian c…”
BackgroundProtein Analysis by Shotgun/Bottom-up Proteomics
Zhang, Y., Fonslow, B. R., Shan, B., Baek, M.-C., & Yates, J. R. (2013) · Chemical Reviews · doi:10.1021/cr3003533 · Cited by 1,491 · cited 1×
“Recently, middle-down method that combined top-down and bottom-up strategies receives attentions in that this method not only can avoid redundant peptides sequences but also can analyze large protein fragments [139].”
BackgroundThe impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262 · cited 1×
“A series of oncometabolites have been identified, including 2hydroxyglutarate and glucose in gliomas and acute myeloid leukemia [226–228], fumarate in papillary kidney cancer [229], succinate in pheochromocytoma [230], sarcosine and choline in Pca [231, 232], glutamine in pancreatic [233, 234], asparagine in ovarian c…”
BackgroundAn inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087 · cited 1×
“A series of oncometabolites have been identified, including 2hydroxyglutarate and glucose in gliomas and acute myeloid leukemia [226–228], fumarate in papillary kidney cancer [229], succinate in pheochromocytoma [230], sarcosine and choline in Pca [231, 232], glutamine in pancreatic [233, 234], asparagine in ovarian c…”
BackgroundHuman metabolic phenotype diversity and its association with diet and blood pressure
Holmes, E., Loo, R. L., Stamler, J., Bictash, M., Yap, I. K. S., Chan, Q., Ebbels, T., De Iorio, M., Brown, I. J., Veselkov, K. A., et al. (2008) · Nature · doi:10.1038/nature06882 · Cited by 1,054
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · cited 1×
“The accumulation of 2-HG inhibits 2-oxoglutarate-dependent oxygenases [240], impairs histone demethylation [241], blocks cell differentiation [242], and promotes tumorigenesis [243].”
BackgroundAmary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023 · cited 1×
“IDH mutations were also identified in multiple cancers, including chondrosarcoma [244], sarcoma [245], and cholangiocarcinoma [246].”
BackgroundNext-generation DNA sequencing techniques
Ansorge, W. J. (2009) · New Biotechnology · doi:10.1016/j.nbt.2008.12.009 · Cited by 993 · cited 2×
“The advantages of second-generation sequencing relative to Sanger sequencing include the higher speed and throughput, cyclic array sequencing to provide with > 10(6) reads/per-array and lower cost, the relatively easier gene library construction, higher degree of parallelism, and more efficient use of reagents [38, 39…”
BackgroundTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · cited 1×
“The accumulation of 2-HG inhibits 2-oxoglutarate-dependent oxygenases [240], impairs histone demethylation [241], blocks cell differentiation [242], and promotes tumorigenesis [243].”
BackgroundCT-based radiomic signature predicts distant metastasis in lung adenocarcinoma
Coroller, T. P., Grossmann, P., Hou, Y., Rios Velazquez, E., Leijenaar, R. T. H., Hermann, G., Lambin, P., Haibe-Kains, B., Mak, R. H., & Aerts, H. J. W. L. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.015 · Cited by 695 · cited 1×
“Another study exploring a set of 635 CT-derived imaging features, including intensity, shape, texture, Laplacian of Gaussian, and wavelet filters, found that 35 and 12 features were related to distant metastasis and survival, respectively [265].”
BackgrounddeFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data
McPherson, A., Hormozdiari, F., Zayed, A., Giuliany, R., Ha, G., Sun, M. G. F., Griffith, M., Heravi Moussavi, A., Senz, J., Melnyk, N., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001138 · Cited by 557 · cited 1×
“The analysis of ovarian cancer RNA-seq data with a novel computational method for fusion discovery—deFuse provides the first gene fusion discovery of ovarian cancer, which may contribute to the study of tumor initiation, development and treatment [91].”
MethodIDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
Diehn, M., Nardini, C., Wang, D. S., McGovern, S., Jayaraman, M., Liang, Y., Aldape, K., Cha, S., & Kuo, M. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801279105 · Cited by 440
Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016
Golubnitschaja, O., Baban, B., Boniolo, G., Wang, W., Bubnov, R., Kapalla, M., Krapfenbauer, K., Mozaffari, M. S., & Costigliola, V. (2016) · EPMA Journal · doi:10.1186/s13167-016-0072-4 · Cited by 396
Wibmer, A., Hricak, H., Gondo, T., Matsumoto, K., Veeraraghavan, H., Fehr, D., Zheng, J., Goldman, D., Moskowitz, C., Fine, S. W., et al. (2015) · European Radiology · doi:10.1007/s00330-015-3701-8 · Cited by 391
Cancer: A Systems Biology disease
Hornberg, J. J., Bruggeman, F. J., Westerhoff, H. V., & Lankelma, J. (2006) · Biosystems · doi:10.1016/j.biosystems.2005.05.014 · Cited by 381
Collins, B. C., Gillet, L. C., Rosenberger, G., Röst, H. L., Vichalkovski, A., Gstaiger, M., & Aebersold, R. (2013) · Nature Methods · doi:10.1038/nmeth.2703 · Cited by 314 · cited 3×
“CAGE Cap analysis of gene expression CID Collision induced dissociation CML Chronic myelogenous leukemia ECD Electro capture dissociation ETD Electron transfer dissociation FTICR Fourier transform ion cyclotron resonance GC Gas chromatography HCC Hepatocellular carcinoma HP Fucosylated haptoglobin HPLC High performanc…”
MethodTargeting TRK family proteins in cancer
Khotskaya, Y. B., Holla, V. R., Farago, A. F., Mills Shaw, K. R., Meric-Bernstam, F., & Hong, D. S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.006 · Cited by 292
Tian, Q., Price, N. D., & Hood, L. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02498.x · Cited by 224
Vignot, S., Frampton, G. M., Soria, J.-C., Yelensky, R., Commo, F., Brambilla, C., Palmer, G., Moro-Sibilot, D., Ross, J. S., Cronin, M. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7737 · Cited by 175
Quantitation and Identification of Thousands of Human Proteoforms below 30 kDa
Durbin, K. R., Fornelli, L., Fellers, R. T., Doubleday, P. F., Narita, M., & Kelleher, N. L. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00997 · Cited by 111 · cited 1×
“Top-down proteomics is able to identify and quantify unique proteoforms through feeding intact full proteins directly into MS, which is capable of providing distinct characteristics of each kind of proteoform with more precise and more abundant biological information [137].”
Background
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Poirion, O. B., Jing, Z., Chaudhary, K., Huang, S., & Garmire, L. X. (2021) · Genome Medicine · doi:10.1186/s13073-021-00930-x · Cited by 297
Integrated multi-omics analysis of ovarian cancer using variational autoencoders
Hira, M. T., Razzaque, M. A., Angione, C., Scrivens, J., Sawan, S., & Sarker, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-85285-4 · Cited by 134
Genome-scale models in human metabologenomics
Mardinoglu, A., & Palsson, B. Ø. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-024-00768-0 · Cited by 54
Patient attrition in Molecular Tumour Boards: a systematic review
Frost, H., Graham, D. M., Carter, L., O’Regan, P., Landers, D., & Freitas, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01922-3 · Cited by 17
Metadata
- Authors
- Lu, M., & Zhan, X.
- Venue
- EPMA Journal
- Published
- 2018-02-21
- Volume
- 9
- Issue
- 1
- Pages
- 77-102
- ISSN
- 1878-5077 (ISSN-L)
- 1878-5085
- OpenAlex
- W2792425071
- Cited by
- 224
- References
- 57
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.